Disease · MONDO_0007039
Trials12
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 12 of 12
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00863122 | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Early phase 1 | 26 | 2018-11-26 | Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor | LAPATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01767792 | Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas | Phase 2 | 22 | 2020-05-27 | Neurofibromatosis Type 2, Progressive Vestibular Schwannomas | BEVACIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00973739 | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Phase 2 | 21 | 2016-03-22 | Neurofibromatosis 2, Vestibular Schwannoma | LAPATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02129647 | Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Phase 2 | 13 | 2021-12-01 | Neurofibromatosis Type 2, Vestibular Schwannomas | AXITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04283669 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Phase 2 | 12 | 2026-03-13 | Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) | CRIZOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01419639 | Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 | Phase 2 | 10 | 2015-08-07 | Neurofibromatosis Type II | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT06553365 | Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors | Phase 2 | 30 | Nerve Sheath Tumor | LUVOMETINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02104323 | Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Phase 2 | 20 | Vestibular Schwannoma, Neurofibromatosis Type 2 | ENDOSTATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00911248 | PTC299 for Treatment of Neurofibromatosis Type 2 | Phase 2 | 11 | Neurofibromatosis 2 | EMVODODSTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT01490476 | Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients | Phase 2 | 10 | Neurofibromatosis 2 | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT02934256 | Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Phase 2 | 10 | Vestibular Schwannoma, Neurofibromatosis Type 2 | ICOTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT01345136 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | Phase 2 | 4 | Neurofibromatosis Type 2, Neuroma, Acoustic | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007039/trials